Search

Displaying results 9081 - 9090 of 10000 in total
  1. Drug

    L-377202

    go.drugbank.com/drugs/DB19022
    Investigational

    L-377202 is under investigation in clinical trial NCT00987753 (Study Evaluating the Safety and Tolerability of L-377202).

  2. Drug

    Pyrrolidone

    go.drugbank.com/drugs/DB19152
    Experimental

    Pyrrolidone is under investigation in clinical trial NCT05444998 (Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for Her2+breast Cancer).

  3. Drug

    Navafenterol

    go.drugbank.com/drugs/DB19195
    Investigational

    Navafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).

  4. Drug

    Cannabidiolic acid

    go.drugbank.com/drugs/DB19261
    Investigational

    Cannabidiolic acid is under investigation in clinical trial NCT04103814 (Effect of Topical CBD Cream for Degenerative Hallux Disorders).

  5. Drug

    Caprospinol

    go.drugbank.com/drugs/DB05263
    Experimental

    Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.

  6. Drug

    Oregovomab

    go.drugbank.com/drugs/DB04964
    Investigational

    Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

  7. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  8. Drug

    VGV-1

    go.drugbank.com/drugs/DB05328
    Experimental

    VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.

  9. Drug

    Cantuzumab ravtansine

    go.drugbank.com/drugs/DB05594
    Investigational

  10. Drug

    Farletuzumab

    go.drugbank.com/drugs/DB05595
    Investigational

    Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.